NGM BIOPHARMACEUTICALS, INC.

(NGM)
  Report
Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
12.78 USD   -0.31%
06/30NGM BIOPHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K)
AQ
06/30NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer
GL
06/30NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NGM BIOPHARMACEUTICALS INC : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)

04/28/2021 | 04:29pm EDT

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

In connection with the 2021 annual meeting of stockholders (the "2021 Annual Meeting") of NGM Biopharmaceuticals, Inc. ("NGM" or the "Company"), the Board of Directors of the Company (the "Board"), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, nominated Roger M. Perlmutter, M.D., Ph.D. for election as a Class II director at the 2021 Annual Meeting as part of the Board's stated objective to evolve the Board's composition to include more members with significant biopharmaceutical industry and operations experience. Particularly in light of the willingness of Dr. Perlmutter to serve as a director if elected, two of NGM's current Class II directors, David Schnell, M.D. and McHenry T. Tichenor, Jr., who have served on the Board since January 2008 and March 2010, respectively, notified NGM on April 26, 2021 that they are resigning from the Board, effective upon the expiration of their respective terms at the 2021 Annual Meeting.

Item 8.01 Other Events.

On April 28, 2021, NGM issued a press release announcing that Dr. Perlmutter has been nominated for election as a Class II director at the 2021 Annual Meeting to be held virtually on Tuesday, June 8, 2021 at 7:30 a.m. Pacific Daylight Time. A copy of the press release titled "NGM Announces Nomination of Roger M. Perlmutter for Election to its Board of Directors" is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

Important Additional Information and Where to Find It

NGM, its directors and certain of its executive officers may be deemed to be participants in the solicitation of proxies from stockholders in connection with the 2021 Annual Meeting. NGM will file with the SEC and make available to its stockholders a proxy statement in connection with such solicitation. NGM STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ SUCH PROXY STATEMENT (INCLUDING ANY AMENDMENTS AND SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.

Information regarding the names of NGM's directors and executive officers and their respective interests in NGM by security holdings or otherwise are set forth in NGM's proxy statement for the 2020 annual meeting of stockholders filed with the SEC on April 8, 2020 and will be set forth in NGM's proxy statement for the 2021 Annual Meeting, which documents are or will be available at NGM's investor relations website at https://ir.ngmbio.com/financial-information/sec-filings. To the extent holdings of such participants in NGM's securities have changed since the amounts described in the 2020 proxy statement, or if a particular participant's holdings are not set forth in the 2020 proxy statement, such holdings (or changes thereto) have been reflected in subsequent statements of beneficial ownership on file with the SEC and will be reflected in NGM's proxy statement for the 2021 Annual Meeting. Information regarding the special interests of such participants, if any, in the matters to be voted on at the 2021 Annual Meeting will be included in the 2021 proxy statement referred to above. You can obtain free copies of these referenced documents as described below.

The proxy statement for the 2021 Annual Meeting (and any amendments or supplements thereto) and any other relevant documents and other material filed by NGM with the SEC, are or will be available for no charge at the SEC's website at www.sec.gov and at NGM's investor relations website at https://ir.ngmbio.com/financial-information/sec-filings. Copies may also be obtained free of charge by contacting NGM by mail at 333 Oyster Point Boulevard, South San Francisco, California 94080, Attn: Secretary, or by telephone at (650) 392-1768.

Item 9.01 Financial Statements and Exhibits.


(d) Exhibits



Exhibit                                  Description

99.1          Press release, dated April 28, 2021, titled "NGM Announces
            Nomination of Roger M. Perlmutter for Election to its Board of
            Directors."

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about NGM BIOPHARMACEUTICALS, INC.
06/30NGM BIOPHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K)
AQ
06/30NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer
GL
06/30NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer
AQ
06/30NGM Biopharmaceuticals, Inc. Announces Executive Changes
CI
06/29TRANSCRIPT : NGM Biopharmaceuticals, Inc. - Special Call
CI
06/23NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022
GL
06/23NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022
AQ
06/14TRANSCRIPT : NGM Biopharmaceuticals, Inc. Presents at Goldman Sachs 43rd Annual Global Hea..
CI
06/13INSIDER BUY : Ngm Biopharmaceuticals
MT
06/06INSIDER BUY : Ngm Biopharmaceuticals
MT
More news
Analyst Recommendations on NGM BIOPHARMACEUTICALS, INC.
More recommendations